Skip to main content

Table 1 Characteristics of participants and study partners analyzed

From: Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer’s disease: study partner vs. participant accuracy

  Amyloid beta elevated (n = 100) Amyloid beta not elevated (n = 235) Total (n = 335)
Sex
 Male 33 (33%) 124 (52.77%) 157 (46.87%)
 Female 77 (77%) 111 (47.23%) 178 (53.13%)
Race/ethnicity
 Caucasian 89 (89%) 212 (90.21%) 301 (89.85%)
 African-American 7 (7%) 15 (6.38%) 22 (6.57%)
 Asian 2 (2%) 4 (1.7%) 6 (1.79%)
Age 74.34 (5.87) 72.8 (5.77) 73.26 (5.83)
Years of education 15.93 (2.56) 16.72 (2.55) 16.49 (2.58)
APOE4 alleles
 0 53 (53%) 182 (77.45%) 235 (70.15%)
 1 43 (43%) 49 (20.85%) 92 (27.46%)
 2 4 (4%) 4 (1.70%) 8 (2.39%)
MMSE 29.04 (1.08) 29.08 (1.28) 29.07 (1.22)
ADAS13 9.63 (4.43) 8.65 (4.42) 8.94 (4.44)
ECog
 Participant 1.42 (0.32) 1.38 (0.33) 1.39 (0.33)
 Study partner 1.21 (0.29) 1.20 (0.30) 1.20 (0.29)